Related Experiment Video
Updated: May 20, 2026
09:39
Mapping Dysfunctional Protein-Protein Interactions in Disease
Published on: October 24, 2025
DPP IV inhibitors: successes, failures and future prospects
Ajay D Kshirsagar1, Ashish S Aggarwal, Uday N Harle
1Department of Pharmacology, Padm. Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune 411018, Maharashtra, India. ksagar.ajay@gmail.com
Diabetes & Metabolic Syndrome
|July 21, 2012
Summary
Dipeptidyl peptidase IV (DPP IV) inhibitors offer a safe and effective treatment for type 2 diabetes, with low hypoglycemia risk. Further research is needed to confirm long-term benefits for beta-cell preservation and overall diabetes management.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Dipeptidyl peptidase IV (DPP IV) is a key target for type 2 diabetes treatment.
- DPP IV inhibitors are emerging as a promising therapeutic class.
Purpose of the Study:
- To review the success, failures, and future prospects of DPP IV inhibitors in managing type 2 diabetes.
- To evaluate the safety, tolerability, and efficacy of DPP IV inhibitors.
Main Methods:
- Literature review of clinical trials and studies on DPP IV inhibitors.
- Analysis of safety, efficacy, and tolerability data.
Main Results:
- DPP IV inhibitors demonstrate safety and tolerability with a low risk of hypoglycemia.
- These agents are effective as monotherapy and in combination with other antidiabetic drugs.
- Once-daily oral dosing is a convenient administration route.
Conclusions:
- DPP IV inhibitors represent a valuable addition to type 2 diabetes pharmacotherapy.
- Long-term studies are required to confirm beta-cell preservation and their role in comprehensive diabetes management.
- Further investigation into managing associated complications is warranted.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...